European journal of clinical pharmacology · 2026
Effect of glucocorticoids on smell sensation in patients with non-traumatic olfactory disorders: a systematic review and meta-analysis.
Систематический обзорСтатьяМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Salimi Sajjad, Amiri Shahin, Karimi Seyed Amir, Babajani Mohammad Mahdi, Rezaiemanesh Alireza
Аннотация
BACKGROUND: The efficacy of glucocorticoids (GCs) for treating non-traumatic olfactory disorders (ODs) remains controversial, with existing meta-analyses showing inconsistent results, largely due to variations in included studies and a lack of etiology-specific analysis.
METHODS: This systematic review and meta-analysis followed a pre-registered protocol (PROSPERO: CRD42022319449). We searched four databases up to December 2025 for studies assessing GCs therapy in adults with non-traumatic ODs. Efficacy was analyzed by etiology, with the primary outcome being the standardized mean difference (SMD) in objective or subjective olfactory score change.
RESULTS: Thirty-four studies were included. GCs therapy significantly improved olfactory function in patients with COVID-19-related ODs (13 studies, 1538 patients, SMD = 0.53, 95% CI: 0.27-0.79), nasal polyposis (9 studies, 2022 patients, SMD = 0.56, 95% CI: 0.39-0.72), and chronic rhinosinusitis with nasal polyps (5 studies, 318 patients, SMD = 0.89, 95% CI: 0.18-1.59). No significant benefit was found for chronic rhinosinusitis without polyps (4 studies, 464 patients, SMD = 0.25, 95% CI: -0.03-0.53) or allergic rhinitis (3 studies, 240 patients, SMD = 0.50, 95% CI: -0.02-1.01). Significant heterogeneity was observed for the positive outcomes. Given the significant heterogeneity (I² > 50%), subgroup analyses were performed based on the method of olfactory assessment, treatment duration, formulation, and control group type.
CONCLUSION: The efficacy of GCs in olfactory dysfunction is probably etiology-dependent. They are most beneficial for ODs related to nasal polyps. For COVID-19-related ODs, short-term intranasal GCs may be effective, while evidence for allergic rhinitis remains inconclusive.
METHODS: This systematic review and meta-analysis followed a pre-registered protocol (PROSPERO: CRD42022319449). We searched four databases up to December 2025 for studies assessing GCs therapy in adults with non-traumatic ODs. Efficacy was analyzed by etiology, with the primary outcome being the standardized mean difference (SMD) in objective or subjective olfactory score change.
RESULTS: Thirty-four studies were included. GCs therapy significantly improved olfactory function in patients with COVID-19-related ODs (13 studies, 1538 patients, SMD = 0.53, 95% CI: 0.27-0.79), nasal polyposis (9 studies, 2022 patients, SMD = 0.56, 95% CI: 0.39-0.72), and chronic rhinosinusitis with nasal polyps (5 studies, 318 patients, SMD = 0.89, 95% CI: 0.18-1.59). No significant benefit was found for chronic rhinosinusitis without polyps (4 studies, 464 patients, SMD = 0.25, 95% CI: -0.03-0.53) or allergic rhinitis (3 studies, 240 patients, SMD = 0.50, 95% CI: -0.02-1.01). Significant heterogeneity was observed for the positive outcomes. Given the significant heterogeneity (I² > 50%), subgroup analyses were performed based on the method of olfactory assessment, treatment duration, formulation, and control group type.
CONCLUSION: The efficacy of GCs in olfactory dysfunction is probably etiology-dependent. They are most beneficial for ODs related to nasal polyps. For COVID-19-related ODs, short-term intranasal GCs may be effective, while evidence for allergic rhinitis remains inconclusive.